Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2024
0mins
Should l Buy ROG?
Source: NASDAQ.COM
Overview of SPDR MSCI EAFE StrategicFactors ETF (QEFA): Launched in 2014, QEFA is a smart beta ETF that aims to outperform traditional market cap weighted indexes by focusing on stocks with favorable risk-return characteristics, and it currently manages over $972 million with an expense ratio of 0.30%.
Performance and Alternatives: The ETF has shown a year-to-date gain of 10.99% and a one-year increase of 18.14%, while investors may also consider other ETFs like iShares MSCI EAFE ETF and iShares Core MSCI EAFE ETF for potentially lower costs and risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROG
Wall Street analysts forecast ROG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 122.340
Low
105.00
Averages
281.18
High
457.36
Current: 122.340
Low
105.00
Averages
281.18
High
457.36
About ROG
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components. Its segments include Advanced Electronics Solutions (AES) and Elastomeric Material Solutions (EMS) and Other. The AES segment designs, develops, manufactures, and sells circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in the EV/HEV, automotive, aerospace and defense, renewable energy, wireless infrastructure, mass transit, industrial, connected devices and wired infrastructure markets. The EMS segment designs, develops, manufactures, and sells engineered material solutions for a variety of applications and markets. These include polyurethane and silicone materials used in cushioning, gasketing and sealing, and vibration management applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, and other markets. The Other segment consists of elastomer components for applications in the general industrial market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Geopolitical Tensions Push Markets into Correction
- Market Correction: Major indices, including the Dow Jones and Nasdaq, fell over 10% due to escalating geopolitical tensions in the Middle East, indicating a significant deterioration in investor sentiment.
- Surge in Oil Prices: The geopolitical instability has led to rising oil prices, exacerbating inflation fears and prompting investors to anticipate a prolonged high-interest rate environment, which negatively impacted overall market performance.
- Stock Performance: HNI, an office furniture company, saw a 3.8% drop, while electronic components manufacturer Rogers fell 3.2%, and enterprise networking firm Cisco declined by 4.1%, reflecting a risk-off sentiment among investors.
- Airlines Benefit: Positive market sentiment linked to falling oil prices boosted shares of American Airlines and United Airlines by 4.9% and 4.5%, respectively, indicating that lower fuel costs will significantly enhance profit margins in these sectors.
See More
Roche Launches New Respiratory Pathogen Test
- Enhanced Detection Capability: Roche's newly launched cobas® eplex respiratory pathogen panel 3 (RP3) can detect up to 250 viruses and bacteria, including SARS-CoV-2 and influenza, enabling doctors to make rapid, critical treatment decisions that are vital for high-risk patients.
- Rapid Result Delivery: Designed for the cobas eplex system, the test is easy to use and can be initiated in less than one minute, significantly reducing patient wait times in emergency rooms and helping hospitals manage isolation beds more effectively to minimize cross-infection risks.
- Clinical Decision Support: The RP3 panel detects over 20 different pathogens simultaneously, allowing clinicians to quickly identify the cause of a patient's illness, start the right treatment sooner, improve patient prognosis, and reduce unnecessary antibiotic use, thereby enhancing healthcare efficiency.
- Flexible Testing Options: The RP3 panel is the first in the cobas eplex family to feature flexible syndromic testing, allowing labs to customize up to five distinct panels based on local prevalence or unique patient presentations, thereby improving detection capabilities for current and emerging pathogens.
See More
Clearline Capital Increases Stake in Core Scientific
- Stake Increase: According to an SEC filing dated February 17, 2026, Clearline Capital LP increased its stake in Core Scientific by 3,436,127 shares, representing 3.37% of its 13F reportable AUM, reflecting confidence in the company's growth potential.
- Market Capitalization Growth: Core Scientific's market capitalization reached $4.95 billion, despite a trailing twelve-month net income of -$280.74 million, indicating strong investor interest in its digital asset infrastructure services.
- Profitability Analysis: Core Scientific's profitability hinges on the difference between Bitcoin market prices and production costs, with key factors such as electricity prices, hardware efficiency, and facility utilization becoming increasingly critical, especially following the recent Bitcoin halving.
- Infrastructure Advantage: Core Scientific is evolving from merely a cryptocurrency miner to a power infrastructure operator, leveraging reliable electricity supply and high-density data center facilities, which provide a competitive edge in the digital asset market.
See More
Clearline Capital Increases Stake in Core Scientific
- Stake Increase: Clearline Capital LP disclosed an increase of 3,436,127 shares in Core Scientific on February 17, 2026, with an estimated transaction value of $59.91 million, reflecting confidence in the company's growth potential.
- Quarter-End Value Growth: Following the increase, the quarter-end position value of Core Scientific rose by $45.79 million, indicating a dual impact from trading activities and stock price appreciation, showcasing the company's robust performance in the digital asset market.
- Holding Proportion Change: Post-trade, Clearline Capital's holdings in Core Scientific reached 4,689,443 shares valued at $68.28 million, accounting for 3.37% of its reportable 13F AUM, although it did not rank among the top five holdings, it still signifies a notable investment position.
- Strong Market Performance: As of February 17, 2026, Core Scientific's share price stood at $17.23, reflecting a 39.1% increase over the past year, outperforming the S&P 500 by 25.81 percentage points, highlighting its competitive edge in the digital asset infrastructure sector.
See More
Clearline Capital Reduces Semtech Holdings Significantly
- Position Reduction Details: According to a February 17, 2026 SEC filing, Clearline Capital LP reduced its position in Semtech by 412,968 shares during Q4 2025, resulting in a quarter-end valuation of $21.07 million, reflecting a $28.87 million decrease due to both share sales and price changes.
- Holding Proportion Analysis: Following this transaction, Semtech now represents 1.04% of Clearline's reportable assets under management, indicating a potential decline in the fund's confidence in Semtech, which may influence market perceptions of the stock.
- Market Performance Overview: As of February 17, 2026, Semtech shares were priced at $87.66, marking a 136.6% increase over the past year, with a one-year alpha of 122.59 percentage points compared to the S&P 500, showcasing the company's strong performance during the semiconductor market recovery phase.
- Investor Watch Points: Semtech is in the recovery phase of the semiconductor cycle, facing inventory pressures and debt burdens; however, its expansion into IoT and connectivity platforms may provide opportunities for long-duration design wins, making it crucial for investors to monitor its ability to achieve stable revenue growth beyond short-term chip cycles.
See More
Clearline Capital Reduces Semtech Holdings
- Share Reduction Details: Clearline Capital LP sold 412,968 shares of Semtech in Q4 2025, with an estimated trade size of $29.30 million, indicating a potential decline in the fund's confidence in the stock.
- Position Value Decline: Post-sale, Clearline's position in Semtech was valued at $21.07 million, a decrease of $28.87 million from the previous quarter, reflecting the impact of both trading activity and stock price fluctuations.
- Asset Management Proportion: Following this transaction, Semtech now represents only 1.04% of Clearline's 13F reportable assets under management, indicating a diminished significance in the fund's overall portfolio.
- Market Performance Analysis: Despite Semtech's stock price increasing by 136.6% over the past year, Clearline's reduction may signal uncertainties regarding future market demand, prompting investors to monitor whether the company can secure long-term design wins in IoT and connectivity platforms.
See More
Geopolitical Tensions Push Markets into Correction
- Market Correction: Major indices, including the Dow Jones and Nasdaq, fell over 10% due to escalating geopolitical tensions in the Middle East, indicating a significant deterioration in investor sentiment.
- Surge in Oil Prices: The geopolitical instability has led to rising oil prices, exacerbating inflation fears and prompting investors to anticipate a prolonged high-interest rate environment, which negatively impacted overall market performance.
- Stock Performance: HNI, an office furniture company, saw a 3.8% drop, while electronic components manufacturer Rogers fell 3.2%, and enterprise networking firm Cisco declined by 4.1%, reflecting a risk-off sentiment among investors.
- Airlines Benefit: Positive market sentiment linked to falling oil prices boosted shares of American Airlines and United Airlines by 4.9% and 4.5%, respectively, indicating that lower fuel costs will significantly enhance profit margins in these sectors.
See More
Roche Launches New Respiratory Pathogen Test
- Enhanced Detection Capability: Roche's newly launched cobas® eplex respiratory pathogen panel 3 (RP3) can detect up to 250 viruses and bacteria, including SARS-CoV-2 and influenza, enabling doctors to make rapid, critical treatment decisions that are vital for high-risk patients.
- Rapid Result Delivery: Designed for the cobas eplex system, the test is easy to use and can be initiated in less than one minute, significantly reducing patient wait times in emergency rooms and helping hospitals manage isolation beds more effectively to minimize cross-infection risks.
- Clinical Decision Support: The RP3 panel detects over 20 different pathogens simultaneously, allowing clinicians to quickly identify the cause of a patient's illness, start the right treatment sooner, improve patient prognosis, and reduce unnecessary antibiotic use, thereby enhancing healthcare efficiency.
- Flexible Testing Options: The RP3 panel is the first in the cobas eplex family to feature flexible syndromic testing, allowing labs to customize up to five distinct panels based on local prevalence or unique patient presentations, thereby improving detection capabilities for current and emerging pathogens.
See More
Clearline Capital Increases Stake in Core Scientific
- Stake Increase: According to an SEC filing dated February 17, 2026, Clearline Capital LP increased its stake in Core Scientific by 3,436,127 shares, representing 3.37% of its 13F reportable AUM, reflecting confidence in the company's growth potential.
- Market Capitalization Growth: Core Scientific's market capitalization reached $4.95 billion, despite a trailing twelve-month net income of -$280.74 million, indicating strong investor interest in its digital asset infrastructure services.
- Profitability Analysis: Core Scientific's profitability hinges on the difference between Bitcoin market prices and production costs, with key factors such as electricity prices, hardware efficiency, and facility utilization becoming increasingly critical, especially following the recent Bitcoin halving.
- Infrastructure Advantage: Core Scientific is evolving from merely a cryptocurrency miner to a power infrastructure operator, leveraging reliable electricity supply and high-density data center facilities, which provide a competitive edge in the digital asset market.
See More
Clearline Capital Increases Stake in Core Scientific
- Stake Increase: Clearline Capital LP disclosed an increase of 3,436,127 shares in Core Scientific on February 17, 2026, with an estimated transaction value of $59.91 million, reflecting confidence in the company's growth potential.
- Quarter-End Value Growth: Following the increase, the quarter-end position value of Core Scientific rose by $45.79 million, indicating a dual impact from trading activities and stock price appreciation, showcasing the company's robust performance in the digital asset market.
- Holding Proportion Change: Post-trade, Clearline Capital's holdings in Core Scientific reached 4,689,443 shares valued at $68.28 million, accounting for 3.37% of its reportable 13F AUM, although it did not rank among the top five holdings, it still signifies a notable investment position.
- Strong Market Performance: As of February 17, 2026, Core Scientific's share price stood at $17.23, reflecting a 39.1% increase over the past year, outperforming the S&P 500 by 25.81 percentage points, highlighting its competitive edge in the digital asset infrastructure sector.
See More
Clearline Capital Reduces Semtech Holdings Significantly
- Position Reduction Details: According to a February 17, 2026 SEC filing, Clearline Capital LP reduced its position in Semtech by 412,968 shares during Q4 2025, resulting in a quarter-end valuation of $21.07 million, reflecting a $28.87 million decrease due to both share sales and price changes.
- Holding Proportion Analysis: Following this transaction, Semtech now represents 1.04% of Clearline's reportable assets under management, indicating a potential decline in the fund's confidence in Semtech, which may influence market perceptions of the stock.
- Market Performance Overview: As of February 17, 2026, Semtech shares were priced at $87.66, marking a 136.6% increase over the past year, with a one-year alpha of 122.59 percentage points compared to the S&P 500, showcasing the company's strong performance during the semiconductor market recovery phase.
- Investor Watch Points: Semtech is in the recovery phase of the semiconductor cycle, facing inventory pressures and debt burdens; however, its expansion into IoT and connectivity platforms may provide opportunities for long-duration design wins, making it crucial for investors to monitor its ability to achieve stable revenue growth beyond short-term chip cycles.
See More
Clearline Capital Reduces Semtech Holdings
- Share Reduction Details: Clearline Capital LP sold 412,968 shares of Semtech in Q4 2025, with an estimated trade size of $29.30 million, indicating a potential decline in the fund's confidence in the stock.
- Position Value Decline: Post-sale, Clearline's position in Semtech was valued at $21.07 million, a decrease of $28.87 million from the previous quarter, reflecting the impact of both trading activity and stock price fluctuations.
- Asset Management Proportion: Following this transaction, Semtech now represents only 1.04% of Clearline's 13F reportable assets under management, indicating a diminished significance in the fund's overall portfolio.
- Market Performance Analysis: Despite Semtech's stock price increasing by 136.6% over the past year, Clearline's reduction may signal uncertainties regarding future market demand, prompting investors to monitor whether the company can secure long-term design wins in IoT and connectivity platforms.
See More
